November 10, 2019 at 3:56 pm

Parallel Advisors LLC Takes Position in Esperion Therapeutics Inc (NASDAQ:ESPR)

by

Parallel Advisors LLC acquired a new stake in Esperion Therapeutics Inc (NASDAQ:ESPR) in the third quarter, HoldingsChannel reports. The institutional investor acquired 7,710 shares of the biopharmaceutical company’s stock, valued at approximately $283,000.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several other hedge funds have also made changes to their positions in ESPR. Marshall Wace LLP acquired a new position in shares of Esperion Therapeutics in the 1st quarter valued at $186,000. Xact Kapitalforvaltning AB acquired a new position in shares of Esperion Therapeutics in the 2nd quarter valued at $203,000. Steward Partners Investment Advisory LLC acquired a new position in shares of Esperion Therapeutics in the 2nd quarter valued at $165,000. Virginia Retirement Systems ET AL acquired a new position in shares of Esperion Therapeutics in the 2nd quarter valued at $219,000. Finally, Bailard Inc. raised its stake in shares of Esperion Therapeutics by 28.1% in the 2nd quarter. Bailard Inc. now owns 76,200 shares of the biopharmaceutical company’s stock valued at $3,545,000 after buying an additional 16,700 shares in the last quarter.

A number of brokerages have recently issued reports on ESPR. Stifel Nicolaus dropped their price objective on shares of Esperion Therapeutics from $112.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, September 17th. BidaskClub raised shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 29th. Northland Securities reaffirmed a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, August 29th. Goldman Sachs Group raised shares of Esperion Therapeutics from a “sell” rating to a “neutral” rating and lowered their target price for the stock from $55.00 to $45.00 in a report on Monday, September 16th. Finally, Cowen reaffirmed a “buy” rating on shares of Esperion Therapeutics in a report on Wednesday. One research analyst has rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $70.44.

Shares of ESPR traded up $0.25 during trading hours on Friday, hitting $37.82. The stock had a trading volume of 592,400 shares, compared to its average volume of 500,623. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -5.02 and a beta of 1.86. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.65 and a quick ratio of 5.65. Esperion Therapeutics Inc has a 52 week low of $33.13 and a 52 week high of $58.90. The company’s fifty day moving average is $38.49 and its two-hundred day moving average is $42.58.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($2.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.42). The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $0.99 million. During the same quarter last year, the company earned ($1.86) EPS. Equities analysts predict that Esperion Therapeutics Inc will post -3.02 EPS for the current fiscal year.

In other news, major shareholder Target N. V. Biotech purchased 80,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average cost of $33.78 per share, for a total transaction of $2,702,400.00. Following the transaction, the insider now directly owns 3,652,964 shares of the company’s stock, valued at approximately $123,397,123.92. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Target N. V. Biotech purchased 75,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was purchased at an average price of $37.30 per share, for a total transaction of $2,797,500.00. Following the completion of the transaction, the insider now directly owns 3,727,964 shares in the company, valued at $139,053,057.20. The disclosure for this purchase can be found here. Insiders purchased a total of 167,500 shares of company stock worth $5,943,925 over the last quarter. 7.70% of the stock is currently owned by corporate insiders.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Featured Story: What is a Tariff?

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Leave a Comment

Your email address will not be published. Required fields are marked *